Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003857 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 636
- Enrollment target
NCT00003857 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 636 participants.
The verdict
NCT00003857, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 636 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. It is not yet known if radiation therapy is more effective than observation, with or without tamoxifen, in treating ductal carcinoma in situ. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with that of observation, with or without tamoxifen, in treating women who have ductal carcinoma in situ.
Interventions
- RADIATION radiation therapy
- PROCEDURE adjuvant therapy
- DRUG tamoxifen citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 636 participants |
| Start Date | 1999-12 |
| Est. Completion | 2022-05-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003857
The ClinicalTrials.gov registry entry for NCT00003857 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 636 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which radiation therapy is the first listed.
NCT00003857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003857 about?
NCT00003857 is a clinical study titled "Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. It is not yet known if radiation therapy is more effect...
What is the current status of trial NCT00003857?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 636 participants. The study started on 1999-12. Estimated completion is 2022-05-20.
What interventions are being tested in trial NCT00003857?
The interventions under investigation include: radiation therapy (RADIATION), adjuvant therapy (PROCEDURE), tamoxifen citrate (DRUG).
Who is sponsoring clinical trial NCT00003857?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.